Global Oncology Biosimilars Market Report 2024

Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Oncology Biosimilars Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Oncology Biosimilars Market Definition And Segments

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy.

The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies.

The oncology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2023 to $8.85 billion in 2024 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars.

The oncology biosimilars market size is expected to see exponentially grown in the next few years. It will grow to $16.48 billion in 2028 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence.

Patent Expirations Drive New Oncology Biosimilars

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for the oncology biosimilars market.

Government-Led Cancer Reduction Initiatives Catalysts For Oncology Biosimilars Market Growth

Government initiatives for reducing cancer are expected to propel the growth of the oncology biosimilars market going forward. Government initiatives refer to actions, policies, or programs introduced and implemented by government authorities at various levels (local, regional, national, or even international) to address specific issues or achieve particular objectives. These initiatives to reduce cancer can create a favorable environment for the development and adoption of oncology biosimilars by providing financial support, regulatory assistance, and public awareness. For instance, in 2022, according to the National Cancer Institute, a US-based government agency, President Biden announced a reignition of the Cancer Moonshot, highlighting new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The Cancer Moonshot is marshaling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention. Therefore, government initiatives for reducing cancer drive the oncology biosimilars market.

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Baxter International Inc., Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Shanghai Henlius Biotech, Viatris Inc., Catalent Inc., Patheon, Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

Unlocking The Potential Addressing The Awareness Gap Among Healthcare Professionals For Oncology Biosimilars

The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.

Fostering Innovation Through Research And Development For Oncology Biosimilars

Pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plans to build a leading immuno-oncology franchise using cash from its commercial biosimilar business.

Increasing Focus On Investments To Support The Battle Of Cancer

Major companies operating in oncology biosimilars are investing in cancer drugs to support the battle of cancer. Company investments in oncology biosimilars emerge as a pivotal bridge between quality cancer care and sustainable healthcare solutions. For instance, in March 2023, Pfizer, a US-based pharmaceutical company merged with Seagen and invested $43 billion to battle cancer. This enhances Pfizer’s presence in the field of oncology and battle against cancer, a leading cause of death worldwide.

North America was the largest region in the global oncology biosimilars market in 2023. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Oncology Biosimilars Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $8.85 billion
Revenue Forecast In 2033 $16.48 billion
Growth Rate CAGR of 16.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Biocon Biologics Limited; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG; Pfizer Inc.; Apotex Inc.; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; BIOCAD; Amgen Inc.; F. Hoffmann-La Roche; Baxter International Inc.; Sanofi SA; Mylan; Samsung Bioepis; Biogen International GmbH; Merck & Co. Inc.; Coherus Biosciences; Eli Lilly and Company; Novartis AG; Shanghai Henlius Biotech; Viatris Inc.; Catalent Inc.; Patheon; Accord Healthcare Ltd.; Zydus Cadila Health Care Limited; Hetero Drugs Limited; Mundipharma International Limited; Mabion SA; Polpharma Biologics; Alvotech; Innovent Biologics; Gan & Lee Pharmaceuticals; Henlius Biotech
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Oncology Biosimilars Market Characteristics

    3. Oncology Biosimilars Market Trends And Strategies

    4. Oncology Biosimilars Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Oncology Biosimilars Market Size and Growth

    5.1. Global Oncology Biosimilars Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Oncology Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Oncology Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Oncology Biosimilars Market Segmentation

    6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Monoclonal Antibody

    Immunomodulators

    Hematopoietic Agents

    Granulocyte Colony-Stimulating Factor (G-CSF)

    6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Breast Cancer

    Colorectal Cancer

    Blood Cancer

    Neutropenia Cancer

    Non-Small Cell Lung Cancer

    Other Cancer Types

    6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    7. Oncology Biosimilars Market Regional And Country Analysis

    7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Oncology Biosimilars Market

    8.1. Asia-Pacific Oncology Biosimilars Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Oncology Biosimilars Market

    9.1. China Oncology Biosimilars Market Overview

    9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Oncology Biosimilars Market

    10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Oncology Biosimilars Market

    11.1. Japan Oncology Biosimilars Market Overview

    11.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Oncology Biosimilars Market

    12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Oncology Biosimilars Market

    13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Oncology Biosimilars Market

    14.1. South Korea Oncology Biosimilars Market Overview

    14.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Oncology Biosimilars Market

    15.1. Western Europe Oncology Biosimilars Market Overview

    15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Oncology Biosimilars Market

    16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Oncology Biosimilars Market

    17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Oncology Biosimilars Market

    18.5. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Oncology Biosimilars Market

    19.9. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Oncology Biosimilars Market

    20.13. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Oncology Biosimilars Market

    21.1. Eastern Europe Oncology Biosimilars Market Overview

    21.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Oncology Biosimilars Market

    22.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Oncology Biosimilars Market

    23.1. North America Oncology Biosimilars Market Overview

    23.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Oncology Biosimilars Market

    24.1. USA Oncology Biosimilars Market Overview

    24.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Oncology Biosimilars Market

    25.1. Canada Oncology Biosimilars Market Overview

    25.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Oncology Biosimilars Market

    26.1. South America Oncology Biosimilars Market Overview

    26.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Oncology Biosimilars Market

    27.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Oncology Biosimilars Market

    28.1. Middle East Oncology Biosimilars Market Overview

    28.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Oncology Biosimilars Market

    29.1. Africa Oncology Biosimilars Market Overview

    29.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Oncology Biosimilars Market Competitive Landscape And Company Profiles

    30.1. Oncology Biosimilars Market Competitive Landscape

    30.2. Oncology Biosimilars Market Company Profiles

    30.2.1. Biocon Biologics Limited

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Celltrion Inc.

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Dr. Reddy's Laboratories Ltd.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Intas Pharmaceuticals Ltd.

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. STADA Arzneimittel AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Oncology Biosimilars Market Competitive Benchmarking

    32. Global Oncology Biosimilars Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Oncology Biosimilars Market

    34. Oncology Biosimilars Market Future Outlook and Potential Analysis

    34.1 Oncology Biosimilars Market In 2028 - Countries Offering Most New Opportunities

    34.2 Oncology Biosimilars Market In 2028 - Segments Offering Most New Opportunities

    34.3 Oncology Biosimilars Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Biocon Biologics Limited Financial Performance
  • Table 75: Celltrion Inc. Financial Performance
  • Table 76: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Table 77: Intas Pharmaceuticals Ltd. Financial Performance
  • Table 78: STADA Arzneimittel AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Biocon Biologics Limited Financial Performance
  • Figure 75: Celltrion Inc. Financial Performance
  • Figure 76: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Figure 77: Intas Pharmaceuticals Ltd. Financial Performance
  • Figure 78: STADA Arzneimittel AG Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Biosimilar Growth Hormones Global Market Report 2024 – By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/ePharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilar Monoclonal Antibodies Global Market Report 2024 – By Type (Synthetic Chemicals, Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Application (Chronic & Autoimmune Diseases, Oncology, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilar Therapeutic Peptides Global Market Report 2024 – By Type (Innovative, Generic), By Route Of Administration (Parenteral Route, Transdermal Route, Other Route Of Administrations), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilar Hormones Global Market Report 2024 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilar Interleukins Global Market Report 2024 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilar Lymphocyte Modulator Global Market Report 2024 – By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Biosimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Biosimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Other Diseases, Distribution Channel (Online Pharmacies, direct to consumer) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Biosimilars Global Market Report 2024 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Pharmaceuticals Global Market Report 2022 – By Type (Pharmaceutical Drugs, Biologics), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, E-Commerce), By Nature (Organic, Conventional) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Frequently Asked Questions

What is the definition of the oncology biosimilars market?

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. For further insights on the oncology biosimilars market, request a sample here

How will the oncology biosimilars market drivers and restraints affect the oncology biosimilars market dynamics? What forces will shape the oncology biosimilars industry going forward?

The oncology biosimilars market growth is aided by expiration of the patent of biologics used for the treatment of cancer. However, some oncology biosimilars market restraints include lack of awareness of biosimilars among primary care physicians (PCPs) and specialists. For further insights on the oncology biosimilars market, request a sample here

What is the forecast market size or the forecast market value of the oncology biosimilars market?

The oncology biosimilars market is expected to reach $12.83 billion in 2027 at a rate of 24.3%. For further insights on the oncology biosimilars market, request a sample here

How is the oncology biosimilars market segmented?

The global oncology biosimilars market is segmented as
1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
For further insights on the oncology biosimilars market, request a sample here

Which region has the largest share of the oncology biosimilars market? What are the largest region's market size and growth rate?

North America was the largest region in the oncology biosimilars market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the oncology biosimilars market?

Key competitors in the oncology biosimilars market are, Biocoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, F Hoffmann-La Roche. For further insights on the oncology biosimilars market, request a sample here.

What are the key trends in the oncology biosimilars market?

Major trends influencing the oncology biosimilars market include increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For further insights on the oncology biosimilars market, request a sample here.

What are the major opportunities in the oncology biosimilars market? What are the strategies for the oncology biosimilars market?

For detailed insights on the major opportunities and strategies in the oncology biosimilars market, request a sample here.

How does the oncology biosimilars market relate to the overall economy and other similar markets?

For detailed insights on oncology biosimilars market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the oncology biosimilars industry?

For detailed insights on the mergers and acquisitions in the oncology biosimilars industry, request a sample here.

What are the key dynamics influencing the oncology biosimilars market growth? SWOT analysis of the oncology biosimilars market.

For detailed insights on the key dynamics influencing the oncology biosimilars market growth and SWOT analysis of the oncology biosimilars industry, request a sample here.